Why rely on Artificial Intelligence (AI)-based drug discovery/hit generation when you can rely on our proven "Real Intelligence (RI)"-based drug discovery using our experimental high-throughput X-ray crystallography platforms ABS-OneStep & ABS-Services to produce "real" empirical 3D protein-ligand interaction information? #drugdiscovery #structuralbiology #crystallography
Accelero Biostructures
Biotechnology Research
San Francisco, CA 474 followers
Protein Crystallography-Driven Structure Based Drug Discovery
About us
Accelero Biostructures accelerates structure-based drug discovery and protein engineering using its Synchrotron-integrated platform for High-Throughput Protein X-ray Crystallography. With a 15-year track record, we are geared toward structure-based drug discovery for pharmaceutical/biotechnology, structure-based protein engineering for industrial enzymes, and academic drug discovery and structural biology projects. We capitalize on 15 years of HT protein x-ray crystal structure determination at the Joint Center for Structural Genomics (JCSG) headed by Prof. Ian A. Wilson at The Scripps Research Institute, La Jolla; Genomics Institute of the Novartis Foundation, La Jolla; Sanford-Burnham Medical Research Institute, La Jolla; and SLAC National Accelerator Laboratory, Menlo Park, with investments from the National Institutes of Health-National Institute of General Medical Sciences' Protein Structure Initiative and considerable investments from participating institutions. JCSG developed a robust gene to structure pipeline. A multi-institutional, industry-like operation with distributed clients was established. The primary drivers were efficiency and cost. More than 1500 novel protein structures were solved, resulting in over 300 publications. Accelero Biostructures has a wealth of experience with proven productivity, with a team of highly trained protein crystallographers with more than 40 years total training and experience at top structural biology laboratories. You can rely on us to provide you with superior protein crystallography and structural biology services.
- Website
-
http://www.accelerobio.com
External link for Accelero Biostructures
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Headquarters
- San Francisco, CA
- Type
- Privately Held
- Founded
- 2015
- Specialties
- Protein X-ray Crystallography, Structure-Based Drug Discovery, Fragment-Based Drug Discovery, and Protein Crystallography Platforms as a Service
Locations
-
Get directions
2nd Street
San Francisco, CA, US
Employees at Accelero Biostructures
Updates
-
Co-Founder & CEO, Preclinical/Early Drug Discovery; SME on Protein X-ray Crystallography, Structural Biology, Biophysics, Chemistry and Structure-, Fragment and AI-Based Drug Discovery (SBDD, FBDD, AIDD).
We are excited to feature in the latest August 2025 issue of Life Sciences Insights, published by California Life Sciences (CLS). Our article “AI Drug Discovery & Development for DNA Damage Response (DDR) Oncology Therapeutics” (https://lnkd.in/gsC3XGC4) on page 14, highlights our efforts to combine our multimodal experimental data for AIDD. This edition, AI in Action: Real-World Innovation in Life Sciences, explores how artificial intelligence is transforming discovery, operations, and patient outcomes across the sector. We are honored to contribute to this important conversation and share our perspective alongside other industry leaders (read the full issue here https://lnkd.in/gc65PVQV). #drugdiscovery #therapeutics Accelero Biostructures XPose Therapeutics
-
-
Co-Founder & CEO, Preclinical/Early Drug Discovery; SME on Protein X-ray Crystallography, Structural Biology, Biophysics, Chemistry and Structure-, Fragment and AI-Based Drug Discovery (SBDD, FBDD, AIDD).
Getting close to wrapping up another great ACA meeting and reconnecting with everyone. Wonderful talks in crystallography/CryoEM/structural biology, materials science, instrumentation, and applications in many areas from applied (drug discovery) to basic sciences. Also a shout out to the great instrument and equipments folks whose products support all this work. #structuralbiology #drugdiscovery
-
-
Co-Founder & CEO, Preclinical/Early Drug Discovery; SME on Protein X-ray Crystallography, Structural Biology, Biophysics, Chemistry and Structure-, Fragment and AI-Based Drug Discovery (SBDD, FBDD, AIDD).
ACA2025 (American Crystallographic Association) annual meeting kicks off today with a plethora of exciting sessions and talks. Looking forward to chairing an AI/ML session, and oral presentations on coupling our crystallography with direct-to-biology degrader design, and fast generation of hits for DDR protein Pol eta. #structuralbiology #drugdiscovery #therapeutics https://lnkd.in/gZwHvbnr
-
-
Why rely on Artificial Intelligence (AI)-based drug discovery/hit generation when you can rely on our proven "Real Intelligence (RI)"-based drug discovery using our experimental high-throughput X-ray crystallography platforms ABS-OneStep & ABS-Services to produce "real" empirical 3D protein-ligand interaction information? #drugdiscovery #structuralbiology #crystallography
-
Co-Founder & CEO, Preclinical/Early Drug Discovery; SME on Protein X-ray Crystallography, Structural Biology, Biophysics, Chemistry and Structure-, Fragment and AI-Based Drug Discovery (SBDD, FBDD, AIDD).
-
Co-Founder & CEO, Preclinical/Early Drug Discovery; SME on Protein X-ray Crystallography, Structural Biology, Biophysics, Chemistry and Structure-, Fragment and AI-Based Drug Discovery (SBDD, FBDD, AIDD).
Nice to see this tour de force in HT protein X-ray crystallography/HT structural biology after a considerable gap from our 15 years (2000-2015) of HT/structural genomics consortia efforts: 55 new crystal structures of bacterial proteins involved in antibiotic modification, cell wall maintenance, oxidative stress and metabolism. https://lnkd.in/gJ-rbRav
-
Co-Founder & CEO, Preclinical/Early Drug Discovery; SME on Protein X-ray Crystallography, Structural Biology, Biophysics, Chemistry and Structure-, Fragment and AI-Based Drug Discovery (SBDD, FBDD, AIDD).
Accepted abstract released for AACR2025 (American Association of Cancer Research) in Chicago in April. Results on XPose Therapeutics compounds in lead optimization (evolved from FBDD/SBDD/fragment hits from Accelero Biostructures screening) being tested in cancer models/cell biology assays by collaborators (Srinivasan Madhusudan) at University of Nottingham, UK. “Novel APE1 endonuclease inhibitors as precision oncology therapeutics in high grade serous ovarian cancers discovered and developed from crystallography-based fragment library screening” https://lnkd.in/g_mmw-7k #oncology #therapeutics #drugdiscovery #structuralbiology #AACR2025
-
-
Exciting new partnership for Accelero Biostructures for Legend portfolio companies. #drugdiscovery #structuralbiology #therapeutics https://lnkd.in/gAht642g
Co-Founder & CEO, Preclinical/Early Drug Discovery; SME on Protein X-ray Crystallography, Structural Biology, Biophysics, Chemistry and Structure-, Fragment and AI-Based Drug Discovery (SBDD, FBDD, AIDD).
Excited to announce a new Accelero Biostructures partnership as a preferred partner for Legend portfolio companies. #drugdiscovery #therapeutics #structuralbiology https://lnkd.in/gDfcwCwn
-
-
Co-Founder & CEO, Preclinical/Early Drug Discovery; SME on Protein X-ray Crystallography, Structural Biology, Biophysics, Chemistry and Structure-, Fragment and AI-Based Drug Discovery (SBDD, FBDD, AIDD).